Apeloa Pharmaceutical
Chinese pharmaceutical manufacturer
From Wikipedia, the free encyclopedia
Apeloa Pharmaceutical Co., Ltd. (Chinese: 普洛药业股份有限公司), known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China.[2][3] It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997 (ticker: 000739).[4][5] Apeloa provides contract development and manufacturing (CDMO) services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.[6][4]
| |
Native name | 普洛药业股份有限公司 |
|---|---|
| Company type | Subsidiary |
| SZSE: 000739 | |
| Industry | Chemicals, Pharmaceutical, Biotechnology |
| Founded | 1989 |
| Products | APIs, FDFs, CDMO services |
| Revenue |
|
| Owner |
|
Number of employees | 7,400+ (2025)[1] |
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development.[7] It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing.[8] In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.[9]
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006.[10]
In 2022, Apeloa Pharmaceutical was one of five Chinese companies licensed to produce Pfizer's oral Covid-19 treatment for lower-income countries.[11] The agreement was signed with the Medicines Patent Pool (MPP), an organization that aims to increase access to drugs in 95 lower-income countries.[12]
Apeloa is a subsidiary of Hengdian Group, a major Chinese private conglomerate founded in 1975 in Hengdian, Zhejiang, with businesses spanning electronics, pharmaceuticals/healthcare, film & tourism, and modern services.[13][14]